Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Active Biotech AB to Present Further Analysis Supporting Effect of ANYARA in Biomarker Defined Subgroup


Thursday, 12 Sep 2013 04:00am EDT 

Active Biotech AB announced that a biomarker trend analysis of overall survival (OS) and Progression Free Survival (PFS) from the ANYARA Phase II/III study in renal cell cancer will be presented at the scientific conference European Cancer Congress 2013 (ECCO-ESMO-ESTRO) held in Amsterdam, the Netherlands, September 27 - October 1. The detailed analysis gives further support to the previous findings that low baseline levels of pre-formed antibodies against ANYARA or low levels of the cytokine IL-6, independently predict anti-tumor efficacy after ANYARA+IFN-alpha treatment. The results also highlight the potential role of IL-6 as a predictive factor for the outcome of immunotherapy of cancer in general. The analysis showed clear trends of increased OS (decreasing Hazard Ratios, HRs) in patients with decreasing IL-6 and anti-ANYARA antibodies. Similar trends were seen for PFS HRs. 

Company Quote

21.9
-0.4 -1.79%
12:29pm EDT